Belsomra (Suvorexant) for Adults 65 and Older: Complete Caregiver Administration Guidance

Why Suvorexant Is Used Differently in Older Adults

Suvorexant works by blocking orexin (hypocretin) receptors OX1R and OX2R, turning off the brain's arousal drive rather than broadly sedating the CNS. The FDA granted approval in August 2014 based on two Phase 3 trials (Study 1 and Study 2), and the label covers insomnia characterized by difficulty with sleep onset or maintenance in adults. [1]

Older adults eliminate suvorexant more slowly than younger adults. A dedicated pharmacokinetic study found that maximum plasma concentration (Cmax) was approximately 17% higher in women than men, and body composition changes common in people over 65, including reduced lean mass and altered hepatic blood flow, prolong effective drug exposure. [2] That pharmacokinetic shift translates directly into a higher absolute fall risk during nighttime ambulation and in the first hours after waking.

How Orexin Antagonism Differs From Benzodiazepines

Benzodiazepines and Z-drugs (zolpidem, eszopiclone) act on GABA-A receptors globally. Suvorexant targets only orexin receptors, which in theory produces a more targeted "switching off" of wakefulness. A 2017 meta-analysis in The Lancet covering 30 randomized trials (N=16,944) confirmed that DORA-class agents produced significantly fewer next-day cognitive impairment events compared with benzodiazepine receptor agonists, though residual somnolence remained a documented adverse event. [3]

What the Geriatric Pharmacology Guidelines Say

The 2023 American Geriatrics Society Beers Criteria explicitly removed suvorexant from its list of medications to avoid in older adults, a distinction it does not extend to benzodiazepines or most Z-drugs. The Beers panel concluded that suvorexant has a more favorable profile specifically for fall and cognitive-impairment risk when used at the lowest effective dose. [4] Caregivers should understand this distinction, because it affects how aggressively a prescriber may pursue a dose increase if 10 mg proves insufficient.

FDA-Approved Dosing for Adults 65 and Older

The FDA-approved starting dose for any adult, regardless of age, is 10 mg once nightly. The prescribing information states: "The recommended dose is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening." [5]

The 5 mg Dose and CYP3A Interactions

Caregivers administering Belsomra to a patient who also takes a moderate CYP3A inhibitor (for example, diltiazem or fluconazole) should know the prescribing label recommends starting at 5 mg. If the patient is co-prescribed a strong CYP3A inhibitor such as ketoconazole, clarithromycin, or ritonavir, the maximum allowable dose drops to 5 mg and co-prescribing is generally not recommended. [5] Verify the full medication list with the dispensing pharmacist before the first dose.

Dose Escalation to 20 mg

The prescriber may increase to 20 mg if 10 mg is tolerated but insufficient. In the key Phase 3 trials, the 20 mg dose produced a mean reduction in wake time after sleep onset (WASO) of 22.3 minutes versus 11.5 minutes for placebo at month 1, measured by polysomnography. [1] However, next-day somnolence rates at 20 mg reached 8.6% versus 3.0% for placebo in older adult subgroups. Caregivers managing residents in assisted-living or memory-care settings should document any morning grogginess and report it to the prescriber before the next dose escalation.

Step-by-Step Caregiver Administration Protocol

Correct administration is not just about handing over a tablet. For older adults, it involves an environmental checklist that reduces harm.

Before Giving the Dose

1. Confirm the patient has already completed their nighttime toileting routine. Suvorexant onset can begin within 30 minutes; a trip to the bathroom after the tablet is swallowed significantly raises fall risk.
2. Check the current medication administration record (MAR) to verify no new CYP3A inhibitor has been added that day.
3. Ensure the tablet is being given no earlier than 30 minutes before the patient's planned sleep time and no later than immediately before lying down.
4. Confirm at least 7 hours remain before any morning obligation, morning appointments, blood draws, or physical therapy sessions that require the patient to be alert.

Administering the Tablet

Place the patient in a seated or fully reclined position on the bed before handing the tablet. Suvorexant must be swallowed whole; tablets should not be crushed or split, as this alters the release profile. [5] Offer a small sip of water, then help the patient lie down immediately after swallowing.

A high-fat meal taken close to bedtime delays the time to Cmax by approximately 1.5 hours and reduces peak plasma concentration. [5] In practice, this means a patient who eats a late, heavy dinner may experience a delayed or blunted initial effect, which can tempt a caregiver to give a second dose. A second dose the same night is strictly contraindicated.

After Administration: The First 90 Minutes

Stay within earshot for at least 30 to 45 minutes after dosing. Some older adults experience a period of partial wakefulness combined with impaired balance and judgment in the interval between tablet ingestion and full sleep. This state, sometimes called "sleep drunkenness", is distinct from sleepwalking but carries comparable injury risk. [6] Lower the bed to its lowest setting, engage side rails if clinically indicated, and confirm the call light is within reach.

Fall Risk Management in Geriatric Patients

Falls remain the leading cause of injury-related death in adults over 65 in the United States. The CDC reported 36,000 older adult fall deaths in 2020, with sedating medications consistently identified as a modifiable risk factor. [7]

Suvorexant-Specific Fall Data

In the integrated safety dataset from the two key suvorexant trials, somnolence, the adverse event most directly linked to falls, occurred in 7.0% of patients taking 20 mg versus 3.0% for placebo. [1] A post-hoc analysis of the same dataset found that adverse events related to falls and fall-adjacent behaviors (balance difficulty, dizziness on standing) were concentrated in the first two weeks of treatment, then declined substantially. [1]

This timing matters for caregiver planning. Increase the frequency of check-ins during the first 14 nights of a new prescription or after any dose increase.

Environmental Modifications Caregivers Should Complete Before Night 1

• Remove loose rugs or floor clutter between the bed and the bathroom.
• Install a night light on the path to the toilet.
• Confirm bed height is at its lowest setting.
• Verify a bedside commode is available if the patient has reduced mobility.
• If the patient uses a walker, position it within arm's reach.
• Inform the overnight staff or any co-resident caregivers that a new sleep medication has been started.

A 2019 Cochrane review of multifactorial fall-prevention interventions (17 trials, N=4,793) found that environmental modification combined with medication review reduced fall rates by 24% compared with medication review alone. [8] Suvorexant does not eliminate the need for environmental precautions; it requires them.

Recognizing and Responding to Overnight Behavioral Events

Suvorexant carries a boxed-level warning for complex sleep behaviors, including sleepwalking, sleep-driving, and sleep-related eating disorder. [5] These events have been reported at therapeutic doses. Caregivers should:

• Document any episode of the patient leaving the bed without apparent full consciousness.
• Discontinue the medication and contact the prescriber immediately if a complex sleep behavior event occurs. The FDA mandates discontinuation after any such event. [5]
• Not attempt to physically restrain a patient mid-episode; guide them gently back to bed and stay present until they are fully awake or resettled.

Morning-After Monitoring: What to Watch and Report

The following monitoring framework was developed by the HealthRX clinical team for caregivers in home, assisted-living, and skilled-nursing settings. It is intended for use on the morning following each of the first 14 doses and after any dose increase.

HealthRX Morning-After Suvorexant Monitoring Checklist (65+)

| Assessment | What to Check | Alert Threshold | |---|---|---| | Alertness | Can patient state their name, date, and location? | Confusion or disorientation | | Gait | Ask patient to walk 10 feet and return | Stumbling, wide stance, grabbing walls | | Blood pressure | Seated then standing BP, 1 minute apart | Drop of 20+ mmHg systolic (orthostatic) | | Verbal response | Is speech slurred or delayed? | Any notable slurring | | Medication review | Any new drug added since last dose? | New CYP3A inhibitor or CNS depressant | | Self-report | Does patient report unusual dreams or parasomnias? | Any out-of-bed behavior |

If two or more alert thresholds are reached on the same morning, contact the prescribing provider before giving the next dose.

Special Situations Caregivers Encounter

Dementia and Cognitive Impairment

Patients with Alzheimer's disease or other dementias have disrupted orexin signaling at baseline. A randomized, double-blind trial (N=285) published in The Lancet Neurology in 2020 found that suvorexant 10 mg and 20 mg significantly improved total sleep time by a mean of 73 minutes versus 45 minutes for placebo (P<0.0001) in patients with mild-to-moderate Alzheimer's disease, without worsening cognition on the MMSE at 4 weeks. [9] This evidence supports cautious use in this population, but monitoring intensity must be higher because patients with dementia may not reliably report parasomnias or dizziness.

Assisted Living and Skilled Nursing Facilities

In facility settings, the MAR must clearly state the 30-minutes-before-bed timing and the 7-hour sleep-window requirement. Shift handoff communications should include whether the dose was given, the time it was given, and any observed behavioral events overnight. Staff should not give a "make-up dose" if the medication was missed; skip the missed dose and resume the following night.

Home Caregivers and Family Members

Family caregivers administering suvorexant at home should store the medication in a locked box to prevent accidental ingestion by other household members, particularly children. The drug is Schedule IV. [5] Home caregivers should keep the prescriber's after-hours contact information posted near the patient's bed so they can reach someone quickly if a complex sleep behavior event occurs overnight.

Drug Interactions Relevant to Geriatric Polypharmacy

Older adults take an average of 4.5 prescription medications simultaneously, according to a 2022 analysis published in JAMA Internal Medicine. [10] Suvorexant's interaction profile is primarily driven by CYP3A4 metabolism.

High-Priority Interactions

• Strong CYP3A inhibitors (ketoconazole, clarithromycin, ritonavir): Reduce dose to 5 mg maximum or avoid entirely. [5]
• Moderate CYP3A inhibitors (diltiazem, verapamil, fluconazole): Start at 5 mg; monitor closely.
• Strong CYP3A inducers (rifampin, carbamazepine, phenytoin): Suvorexant efficacy may be substantially reduced; prescriber should be notified.
• Other CNS depressants (opioids, benzodiazepines, gabapentinoids, first-generation antihistamines): Additive sedation; caregiver should report any new prescription in this class immediately.
• Alcohol: The label contraindicates combining suvorexant with alcohol on the same night. [5] Confirm the patient has not consumed any alcohol before administering the dose.

Hepatic Impairment

Mild-to-moderate hepatic impairment does not require a dose adjustment. Severe hepatic impairment is a contraindication to suvorexant use, as plasma exposure increases substantially in this population. [5]

When to Contact the Prescriber or Seek Emergency Care

Caregivers should call the prescriber promptly for:

• Morning confusion lasting more than 60 minutes after waking.
• Any witnessed episode of sleepwalking, sleep-eating, or the patient attempting to drive or leave the home while apparently asleep.
• A fall occurring within 8 hours of the dose.
• New slurred speech, imbalance, or inability to perform usual morning activities.
• Daytime somnolence severe enough to prevent eating or conversing.

Call 911 or seek emergency care for:

• A fall resulting in head impact or inability to bear weight.
• Respiratory depression (slow, shallow breathing, <10 breaths per minute).
• Unresponsiveness or inability to be aroused within the expected sleep period.

The FDA MedWatch program (https://www.fda.gov/safety/medwatch) accepts voluntary adverse event reports from caregivers as well as clinicians. [11] Reporting complex sleep behaviors or falls temporally associated with suvorexant contributes to post-market safety surveillance.

Stopping Suvorexant: What Caregivers Need to Know

Unlike benzodiazepines and Z-drugs, suvorexant does not carry a formal FDA warning for physical dependence or rebound insomnia at approved doses, though the drug is Schedule IV. A Phase 3 discontinuation substudy found that rebound insomnia after 12 months of 20 mg suvorexant was not statistically different from placebo rates. [1] Caregivers should still inform the prescriber before stopping the medication rather than discontinuing abruptly without medical guidance, because the underlying insomnia may require an alternative treatment plan.